O artigo Neuroinflammation and amyloid load in different age groups of individuals with Down syndrome: A PET imaging study pode ser lido em: alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.70449.
Abstract
INTRODUCTION
Down syndrome (DS) is associated with early-onset Alzheimer’s disease (AD). This study evaluated neuroinflammation and amyloid beta (A?) load in individuals with DS of different ages, using positron emission tomography (PET) imaging.
METHODS
DS (n = 29) and age-matched non-DS (n = 35) individuals underwent [11C]PK11195 and [11C]PiB (Pittsburgh compound B) PET scans, for assessment of neuroinflammation and A? load, respectively. Voxel-wise and region-based analyses were conducted, and associations between [11C]PK11195 binding and A? load were investigated.
RESULTS
Individuals with DS exhibited increased [11C]PK11195 binding compared to non-DS controls, with most pronounced differences in older (?50 years) adults, followed by younger (20–34 years), and intermediate (35–49 years) ages. Among DS participants, 13 individuals were amyloid positive. Associations were observed between [11C]PK11195 binding and global A? load.
DISCUSSION
Neuroinflammation in DS follows a region-specific pattern, partially associated with amyloid deposition, and may contribute to the early progression of AD-related pathology.
Highlights
Neuroinflammation is elevated in Down syndrome (DS) versus age-matched non-DS controls.
Neuroinflammation in DS shows a different pattern depending on the brain region.
[11C]PK11195 uptake has a positive monotonic association with amyloid burden.
1 BACKGROUND
Down syndrome (DS) is the most common cause of intellectual disability worldwide, with ?5.8 million individuals affected.1 Individuals with DS can present critical health conditions, such as congenital heart disease, hypothyroidism, and autoimmune diseases, leading to reduced life expectancy, as well as neurological conditions, including early-onset Alzheimer’s disease (AD).1 In recent years, the lifespan of individuals with DS has increased significantly, from 25 years in 1983 to 60 years in 2020, surpassing the extension observed in the general population.2 However, this increase in life expectancy has not been accompanied by a corresponding extension of health span. Individuals with DS experience an accelerated and premature aging phenotype, characterized by elevated levels of molecular markers and mechanisms associated with aging.3 Clinically, the signs of early aging particularly affect the neurological system, primarily driven by the near-universal neuropathology of AD.4
AD is the most prevalent cause of dementia and is characterized by a range of neuropathological changes, including the accumulation of amyloid beta (A?) plaques and neurofibrillary tangles, along with a pro-inflammatory state, all of which can be identified in vivo through imaging biomarkers and biofluids.5, 6 The risk of AD in DS is >90% by the seventh decade of life.7, 8 This higher risk has been associated with the increased expression of the A? precursor protein (APP) gene and the dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (DYRK1A) in the trisomic chromosome 21, leading to elevated production and aggregation of the neurotoxic A?42 peptide, hyperphosphorylation of tau protein, and endosomal dysfunctions in trisomic neurons, the hallmarks of AD.9-12
Neuroinflammation has been considered a relevant factor associated with AD pathology. Significant evidence links inflammatory mechanisms and microglial activation to the deposition of A? plaques in AD.13-19 Aggregates of A? plaque induce microglial activation and can lead to neural death by releasing nitric oxide, reactive oxygen species, and chemokines.20 The presence of neuroinflammation may accelerate the onset of AD in individuals with DS, anticipating its onset in individuals in their 40s.21 In addition, increased cytokines, such as interleukin 6 (IL-6) and IL-8, were described in postmortem brain tissue in DS.22
Research on the in vivo neuroinflammatory process in DS is crucial but limited in the literature. Therefore, the current study aimed to characterize neuroinflammation and amyloid load across different age groups in individuals with DS using positron emission tomography (PET) imaging with [11C]PK11195 and [11C]PiB (Pittsburgh compound B).
2 METHODS
2.1 Diversity, equity, and inclusion statement
This study was conducted in accordance with principles of diversity, equity, and inclusion. Individuals with DS were recruited without discrimination regarding sex, ethnicity, or socioeconomic status. Although our sample reflects the demographic composition of the local DS population, we acknowledge that it does not capture broader ethnic and socioeconomic diversity. All procedures were designed to accommodate cognitive and behavioral heterogeneity in participants with DS, ensuring inclusive access to neuroimaging research. The research team comprises investigators from diverse academic, gender, and professional backgrounds, reinforcing our commitment to collaborative and equitable science.
Fonte: https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.70449